Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A

Transplant Proc. 1994 Oct;26(5):2644-5.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Alanine Transaminase / blood
  • Alkaline Phosphatase / blood
  • Aspartate Aminotransferases / blood
  • Cholesterol / blood*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Cholesterol, VLDL / blood
  • Creatinine / blood
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use*
  • Follow-Up Studies
  • Heart Transplantation / immunology*
  • Heart Transplantation / physiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Lovastatin / analogs & derivatives*
  • Lovastatin / therapeutic use
  • Pravastatin / blood
  • Pravastatin / pharmacokinetics*
  • Simvastatin
  • Time Factors
  • Triglycerides / blood

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cholesterol, VLDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Triglycerides
  • Cyclosporine
  • Cholesterol
  • Lovastatin
  • Simvastatin
  • Creatinine
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Alkaline Phosphatase
  • Pravastatin